Maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, and unconjugated estriol levels in midtrimester trisomy 18 pregnancies
- PMID: 1375811
- DOI: 10.1016/0002-9378(92)91610-m
Maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, and unconjugated estriol levels in midtrimester trisomy 18 pregnancies
Abstract
Objective: The purpose was to evaluate the levels of maternal serum human chorionic gonadotropin, alpha-fetoprotein, and unconjugated estriol in trisomy 18 pregnancies compared with normal singleton pregnancies.
Study design: Sera from 14 trisomy 18 pregnancies (13 retrospectively and one prospectively ascertained) were analyzed for human chorionic gonadotropin, alpha-fetoprotein, and unconjugated estriol.
Results: The alpha-fetoprotein levels in the 10 trisomy 18 pregnancies without open neural tube or ventral wall defect had a median of 0.65 multiple of the median, although two had alpha-fetoprotein levels above 2.5 multiples of the median. The human chorionic gonadotropin levels had a median of 0.32 multiple of the median and the unconjugated estriol levels had a median of 0.56 multiple of the median. Although most women with trisomy 18 pregnancies had serum human chorionic gonadotropin levels that were less than 1.0 multiple of the median, three had markedly elevated human chorionic gonadotropin levels (greater than 5.0 multiples of the median).
Conclusion: Our data are partially consistent with those previously published but suggest the possibility of a bimodal distribution of alpha-fetoprotein and human chorionic gonadotropin levels in trisomy 18-affected pregnancies, unrelated to a neural tube or abdominal wall defect. The efficiency of screening for trisomy 18 prospectively, using the three serum markers, requires further evaluation.
Similar articles
-
Prenatal screening for trisomy 18 with free beta human chorionic gonadotrophin as a marker.BMJ. 1993 Dec 4;307(6917):1455-8. doi: 10.1136/bmj.307.6917.1455. BMJ. 1993. PMID: 7506599 Free PMC article.
-
A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol.Am J Obstet Gynecol. 1993 Sep;169(3):526-30. doi: 10.1016/0002-9378(93)90613-n. Am J Obstet Gynecol. 1993. PMID: 7690522 Clinical Trial.
-
Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome.Am J Obstet Gynecol. 1999 Oct;181(4):968-74. doi: 10.1016/s0002-9378(99)70334-0. Am J Obstet Gynecol. 1999. PMID: 10521763
-
Obstetrical complications associated with abnormal maternal serum markers analytes.J Obstet Gynaecol Can. 2008 Oct;30(10):918-932. doi: 10.1016/S1701-2163(16)32973-5. J Obstet Gynaecol Can. 2008. PMID: 19038077 Review. English, French.
-
Prospective evaluation of prenatal maternal serum screening for trisomy 18.Am J Obstet Gynecol. 1998 Mar;178(3):446-50. doi: 10.1016/s0002-9378(98)70418-1. Am J Obstet Gynecol. 1998. PMID: 9539506 Review.
Cited by
-
Prenatal screening for trisomy 18 with free beta human chorionic gonadotrophin as a marker.BMJ. 1993 Dec 4;307(6917):1455-8. doi: 10.1136/bmj.307.6917.1455. BMJ. 1993. PMID: 7506599 Free PMC article.
-
Mechanisms of alphafetoprotein transfer in the perfused human placental cotyledon from uncomplicated pregnancy.J Clin Invest. 1995 Nov;96(5):2220-6. doi: 10.1172/JCI118277. J Clin Invest. 1995. PMID: 7593608 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources